CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0524 (clinicaltrials.gov NCT No: NCT00210665)
Title:A Multicenter Open-Label Single-Arm Study of YONDELIS® (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Principal Investigator:Shreyaskumar R. Patel
Treatment Agent:Dexamethasone; ET-743
Study Status:Open
Study Description:The goal of this clinical research study is to give previously treated patients
with soft tissue sarcoma access to the experimental drug trabectedin (ET-743,
YONDELIS) before it becomes commercially available. The safety of trabectedin
will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Sarcoma
Phase of Study:N/A
Treatment Agents:Dexamethasone
ET-743
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Laboratory testing on Day 1 and midway through the cycle (more often if
clinically necessary) and every 3 weeks for laboratory testing and chemotherapy
administration.
Home Care:Supportive care.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Shreyaskumar R. Patel
Dept:Sarcoma Medical Oncology
For Clinical Trial Enrollment:713-792-3626
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults